Skip to main navigation Skip to search Skip to main content

Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

  • Surya P. Bhatt*
  • , Klaus F. Rabe*
  • , Nicola A. Hanania
  • , Claus F. Vogelmeier
  • , Jeremy Cole
  • , Mona Bafadhel
  • , Stephanie A. Christenson
  • , Alberto Papi
  • , Dave Singh
  • , Elizabeth Laws
  • , Leda P. Mannent
  • , Naimish Patel
  • , Heribert W. Staudinger
  • , George D. Yancopoulos
  • , Eric R. Mortensen
  • , Bolanle Akinlade
  • , Jennifer Maloney
  • , Xin Lu
  • , Deborah Bauer
  • , Ashish Bansal
    • Lacey B. Robinson, Raolat M. Abdulai
*Corresponding author for this work
  • Allergy
  • University of Alabama at Birmingham
  • University of Kiel
  • Baylor College of Medicine
  • Philipps-Universitat
  • OK Clinical Research
  • University of California, San Francisco
  • University of Ferrara
  • Manchester University NHS Foundation Trust
  • Sanofi S.A.
  • Sanofi
  • Regeneron Pharmaceuticals, Inc.

Research output: Contribution to journal › Article › peer-review

435 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology